In May 2011, the FDA issued new guidance for the submission of summary bioequivalence data for abbreviated new drug applications (ANDAs). This new guidance means that all bioequivalence data will now have to be submitted, including failed studies.
FDA issues new bioequivalence guidance for generics
Home/Guidelines | Posted 06/06/2011 0 Post your comment
The new guidance is meant to clarify the requirements for the submission of bioequivalence data that were published in 2009 [1]. This is a significant change that requires ANDA applicants to disclose all bioequivalence studies conducted on a drug product formulation submitted for approval, even those that do not demonstrate that the generic product meets the current bioequivalence criteria. This could result in it becoming more difficult for generic drug companies to establish bioequivalence in the US.
Types of ANDA submissions which must include all bioequivalence studies are the following:
- ANDAs (section 314.94)
- ANDA amendments (section 314.96(a))
- ANDA supplements that require BE studies under section 320.21(c)
- ANDAs submitted under a suitability petition (section 314.93)
- ANDA annual reports (section 314.81(b)(2)(vi))
The guidance also specifies the necessary format for the summary report to be provided, and clarifies what the meaning of ‘the same product formulation’ for immediate-release drug forms, extended-release drug products, semisolid dosage forms, and other complex dosage forms. This guidance also contains examples of slightly different formulations that would be considered the same product, and of other formulations that would be considered different.
Related articles
Reference
1. FDA. Requirements for submission of bioequivalence data; final rule. Fed. Regist. 2009;74(11):2849–62.
Policies & Legislation
Strategic plans of ANVISA and COFEPRIS to advance health regulation
Panama enacts new bill to guarantees the supply of medicines
Reports
Follow-on biological/biosimilar approvals in Latin America by therapeutic class
Follow-on biological/biosimilar approvals landscape in Latin America
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
New decree for the prescription and commercialization of medicines in Argentina
FDA issues draft guidance on biosimilars and interchangeable biosimilars labelling
WHO’s revised guideline to safe and effective biosimilar products
New FDA guidance on statistical approaches to establishing bioequivalence
Comments (0)
Post your comment